BAYER

**Bayer-THU Collaboration**

*Call for Application*

# 2024 Bayer Investigator Award

Collaborate to Cure Hub China
Bayer Pharmaceuticals

拜耳处方药中国合作创新中心

Dec 2024

# Introduction

**Collaborate**
TO **CURE**

## About Bayer Investigator Award

**Bayer Investigator Award** is presented annually to Tsinghua University Investigators in recognition of their scientific excellence in the research field relevant to Bayer Pharma R&D. Selected Bayer Investigators will get the following supports:

// Grant of CNY 150,000 for each selected Bayer Investigator

// Get connected for potential research collaboration discussion

## Who May Apply?

**Eligibility criteria** of the Bayer Investigators are:

// Full-time employees of THU at the time of applying and receiving the award

// Working in the School of Life Sciences, Tsinghua Medicine, School of Pharmaceutical Sciences or Department of Chemistry of Tsinghua

// Independent of having a project with Bayer or not

// **Must not** be healthcare professionals, or employed by a hospital due to international compliance requirements

// Members of the Joint Steering Committee (JSC) may not apply for the award

// Have not been selected as Bayer Investigator in the previous 36 months

RESTRICTED

**Collaborate** TO **CURE**

# Selection

## Considerations

Research excellence, e.g. publication records over the past five years (2019 – 2024)

Research relevance to **Bayer's areas of interest**

## Decision

Selection will be conducted by the Joint Steering Committee (JSC) from both Bayer and Tsinghua University

👍 **Therapeutic areas** in **Precision Oncology** (e.g. Precision molecular oncology, Targeted Radiotherapies, Next-gen Immuno-Oncology, ADCs), **Precision cardiorenal diseases** (e.g. Heart Failure, Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Chronic Kidney Disease, Autosomal Dominant Kidney Disease, Lupus Nephritis), **Neurology & Rare diseases** enabled by cell and gene therapy, and **Immunology & Inflammation** (e.g. SLE, IBD).

👍 **Novel technologies / platforms** that enable target identification/entry into druggability, specifically:

👍 Interactome analysis, methods for identification of new allosteric pockets and binders, multi-omics techniques, structural biology and biophysical methods (e.g. X-Ray, cryo-EM, AS MS, NMR, etc.), bioinformatics

👍 Acceleration of learning cycles: Organ on drug to accelerate insights generation for new targets and cps, Prediction/ data science aspects specifically for acceleration of learning cycles

👍 **Therapeutic modalities**

👍 Peptide binders, protein degraders, molecular glue, modalities derived from conjugation platforms (antibody, peptide, glyco, radio labelling), SMOL RNA binders, Antisense and siRNA therapeutics

👍 Targeted drug delivery: e.g. organ specific LNPs, etc.

RESTRICTED

**Collaborate** TO CURE

# Application Process

**1** **Fill out the Application Form, which includes:**

// A short description of research interests and achievements

// A list of relevant publications, and publications aligned with Bayer's areas of interest (if any)

// Curriculum Vitae

**2** **Submit your application to Bayer and THU Alliance Managers:**

Duan Wang(王端)

Collaborate to Cure Hub China
Bayer Pharmaceuticals

Mobile: +86 18221448381
E-mail: duan.wang@bayer.com

Yuxin Li(李玉鑫)

Biomedical Innovation Office, Tsinghua University

Tel: +86 10 62781816
Mobile: +86 13848615270
E-mail: yuxin-li@mail.tsinghua.edu.cn

**3** **Application deadline is Jan 27th, 2025.**

**4** **Decision letters will be sent out in February 2025**